Plasma Adiponectin Levels in Relation to Chronic Hepatitis B Infection Progression to Liver Cancer Milestones: A...

Area of Science:

• Hepatology
• Viral Hepatitis Research
• Cancer Biomarkers

Background:

• Previous studies indicated a link between elevated adiponectin and increased risk of liver cirrhosis and hepatocellular carcinoma (HCC) in Hepatitis B virus (HBV) carriers.
• The REVEAL-HBV cohort provided an opportunity to prospectively investigate the direct effects of adiponectin on end-stage liver diseases and HBV progression.

Purpose of the Study:

• To prospectively evaluate the association between baseline plasma adiponectin levels and subsequent HBV seroclearance (HBeAg, HBsAg, HBV DNA).
• To assess the relationship between adiponectin and the development of liver cirrhosis, HCC, and liver-related death in HBV carriers.
• To examine whether HBV characteristics modify the associations between adiponectin and these clinical milestones.

Main Methods:

• Analysis of baseline plasma adiponectin in 3,684 participants from the REVEAL-HBV cohort (HBsAg(+)/anti-HCV(-)).
• Investigation of associations with HBeAg, HBsAg, and HBV DNA seroclearance, and development of cirrhosis, HCC, and liver-related death.
• Examination of effect modification by HBV genotype on adiponectin-milestone associations.

Main Results:

• Elevated adiponectin showed a dose-response association with higher odds of HBeAg-seropositivity, high HBV viral load, and high HBsAg titers.
• Higher adiponectin levels were associated with lower rates of HBeAg, HBsAg, and HBV DNA seroclearance.
• Participants with the highest adiponectin quintile had significantly increased risks of developing liver cirrhosis, HCC, and liver-related death.
• HBV genotype C significantly modified the associations between adiponectin and HCC risk and liver-related death.

Conclusions:

• Elevated adiponectin is consistently associated with key milestones in chronic HBV infection that lead to liver cancer.
• The precise mechanisms by which adiponectin influences HBV infection and carcinogenesis require further investigation.
• Understanding these mechanisms could lead to novel therapeutic targets, improved HBV surveillance biomarkers, and enhanced cancer prevention strategies.